Corporate Profile

AlloSite Therapeutics is pioneering a significant shift in how the clinically validated integrin receptors are therapeutically targeted. We are developing allosteric activators as a new therapeutic modality for targeting integrins, and are also applying our robust, AI- and Machine-learning driven technology to develop first-in-class medicines. 

AlloSite Therapeutics is a clinical stage biotechnology company developing transformative kidney disease therapeutics. We are an expert team of drug developers with deep knowledge of integrin biology and machine learning, and we are applying this core knowledge for making novel medicines for patients with high unmet need- especially in kidney disease. 

Our key idea, “allosteric activation” of integrins as a therapeutic approach, has been pioneered by the company’s co-founder, Vineet Gupta, PhD, that opens up a number of integrins as therapeutic targets that are not available to the traditional ligand-site antagonist approach. 

We are partnering with the leading pharmaceutical companies and welcome inquiries for collaboration and partnerships.